RU2020115045A - Азотсодержащее гетероарильное соединение и его фармацевтическое применение - Google Patents
Азотсодержащее гетероарильное соединение и его фармацевтическое применение Download PDFInfo
- Publication number
- RU2020115045A RU2020115045A RU2020115045A RU2020115045A RU2020115045A RU 2020115045 A RU2020115045 A RU 2020115045A RU 2020115045 A RU2020115045 A RU 2020115045A RU 2020115045 A RU2020115045 A RU 2020115045A RU 2020115045 A RU2020115045 A RU 2020115045A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- halogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 22
- 150000003839 salts Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 201000001431 Hyperuricemia Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 108091006303 SLC2A9 Proteins 0.000 claims 4
- 102100022720 Solute carrier family 2, facilitated glucose transporter member 6 Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 claims 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001924 cycloalkanes Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017194005 | 2017-10-04 | ||
| JP2017-194005 | 2017-10-04 | ||
| PCT/JP2018/037007 WO2019069973A1 (ja) | 2017-10-04 | 2018-10-03 | 含窒素ヘテロアリール化合物およびその医薬用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020115045A true RU2020115045A (ru) | 2021-11-08 |
Family
ID=65994698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020115045A RU2020115045A (ru) | 2017-10-04 | 2018-10-03 | Азотсодержащее гетероарильное соединение и его фармацевтическое применение |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10752596B2 (enExample) |
| EP (1) | EP3693358B1 (enExample) |
| JP (1) | JP7125882B2 (enExample) |
| KR (1) | KR20200064101A (enExample) |
| CN (1) | CN111148735B (enExample) |
| AR (1) | AR113270A1 (enExample) |
| AU (1) | AU2018345221A1 (enExample) |
| BR (1) | BR112020004857A2 (enExample) |
| CA (1) | CA3074989A1 (enExample) |
| CL (1) | CL2020000898A1 (enExample) |
| CO (1) | CO2020003977A2 (enExample) |
| IL (1) | IL273573A (enExample) |
| MX (1) | MX2020003816A (enExample) |
| PE (1) | PE20200846A1 (enExample) |
| PH (1) | PH12020550403A1 (enExample) |
| RU (1) | RU2020115045A (enExample) |
| SG (1) | SG11202003005PA (enExample) |
| TW (1) | TW201922706A (enExample) |
| WO (1) | WO2019069973A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110156698B (zh) * | 2019-06-06 | 2020-10-13 | 沈阳海诺威医药科技有限公司 | 2-苯基-1，6-二氢嘧啶-5-甲酸衍生物的制备方法和用途 |
| CN113181206B (zh) * | 2021-04-30 | 2023-07-14 | 青岛大学 | 与高尿酸血症伴高血脂、高血糖治疗相关基因SLC2A9的siRNA及其应用 |
| IL313713A (en) * | 2022-01-07 | 2024-08-01 | Horizon Therapeutics Ireland Dac | Heterocyclic inhibitors of glut9 for treatment of disease |
| CN114805192B (zh) * | 2022-03-30 | 2023-05-23 | 华南理工大学 | 一种含2-羟基苯甲酸的三环类xor/urat1双重抑制剂及其制备方法与应用 |
| WO2024167952A1 (en) * | 2023-02-08 | 2024-08-15 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oxidatively cleavable organophosphate drugs |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861419A (en) | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
| SK283261B6 (sk) * | 1996-07-18 | 2003-04-01 | Merck Frosst Canada & Co. / Merck Frosst Canada & Cie. | Substituované pyridíny, farmaceutický prostriedok s ich obsahom a ich použitie |
| BR9910122A (pt) * | 1998-04-10 | 2001-10-16 | Japan Tobacco Inc | Compostos amidina |
| WO2005013907A2 (en) * | 2003-08-07 | 2005-02-17 | Japan Tobacco Inc. | Pyrrolo[1,2-b]pyridazine derivatives |
| CA2606288A1 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| JP2007176933A (ja) * | 2005-11-29 | 2007-07-12 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| JP5162827B2 (ja) | 2005-12-27 | 2013-03-13 | ぺんてる株式会社 | 鉛筆芯の製造方法 |
| JP5330990B2 (ja) | 2007-04-11 | 2013-10-30 | キッセイ薬品工業株式会社 | 含窒素複素環化合物およびそれを含有する医薬組成物 |
| JP2009016193A (ja) * | 2007-07-05 | 2009-01-22 | Daihen Corp | 電気機器用樹脂ブッシング |
| DK2455381T5 (en) * | 2009-07-17 | 2015-02-09 | Japan Tobacco Inc | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by |
| CA2794266C (en) | 2010-03-24 | 2020-09-08 | Ohio University | Compositions and methods for glucose transport inhibition |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| CN105439946B (zh) * | 2014-08-13 | 2018-02-02 | 益方生物科技（上海）有限公司 | 羧酸化合物及其制备方法和用途 |
| CN104306363B (zh) * | 2014-10-31 | 2017-06-06 | 南京葆赫生物技术有限公司 | 芪类衍生物及其药学可接受的盐在制备治疗高尿酸血症药物中的应用 |
-
2018
- 2018-10-03 PE PE2020000529A patent/PE20200846A1/es unknown
- 2018-10-03 BR BR112020004857-7A patent/BR112020004857A2/pt not_active Application Discontinuation
- 2018-10-03 US US16/150,989 patent/US10752596B2/en active Active
- 2018-10-03 CN CN201880064738.0A patent/CN111148735B/zh active Active
- 2018-10-03 TW TW107134941A patent/TW201922706A/zh unknown
- 2018-10-03 WO PCT/JP2018/037007 patent/WO2019069973A1/ja not_active Ceased
- 2018-10-03 AU AU2018345221A patent/AU2018345221A1/en not_active Abandoned
- 2018-10-03 EP EP18864398.5A patent/EP3693358B1/en active Active
- 2018-10-03 AR ARP180102853A patent/AR113270A1/es unknown
- 2018-10-03 CA CA3074989A patent/CA3074989A1/en not_active Abandoned
- 2018-10-03 MX MX2020003816A patent/MX2020003816A/es unknown
- 2018-10-03 RU RU2020115045A patent/RU2020115045A/ru unknown
- 2018-10-03 KR KR1020207012149A patent/KR20200064101A/ko not_active Withdrawn
- 2018-10-03 SG SG11202003005PA patent/SG11202003005PA/en unknown
- 2018-10-03 JP JP2018188038A patent/JP7125882B2/ja active Active
-
2020
- 2020-03-24 IL IL273573A patent/IL273573A/en unknown
- 2020-03-31 CO CONC2020/0003977A patent/CO2020003977A2/es unknown
- 2020-04-02 CL CL2020000898A patent/CL2020000898A1/es unknown
- 2020-04-06 PH PH12020550403A patent/PH12020550403A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20190152926A1 (en) | 2019-05-23 |
| SG11202003005PA (en) | 2020-04-29 |
| WO2019069973A1 (ja) | 2019-04-11 |
| IL273573A (en) | 2020-05-31 |
| MX2020003816A (es) | 2020-08-13 |
| CN111148735A (zh) | 2020-05-12 |
| AU2018345221A1 (en) | 2020-05-07 |
| CA3074989A1 (en) | 2019-04-11 |
| CN111148735B (zh) | 2023-08-08 |
| PH12020550403A1 (en) | 2021-02-15 |
| BR112020004857A2 (pt) | 2020-09-15 |
| CO2020003977A2 (es) | 2020-04-24 |
| EP3693358B1 (en) | 2023-02-22 |
| KR20200064101A (ko) | 2020-06-05 |
| EP3693358A1 (en) | 2020-08-12 |
| PE20200846A1 (es) | 2020-08-18 |
| US10752596B2 (en) | 2020-08-25 |
| JP7125882B2 (ja) | 2022-08-25 |
| AR113270A1 (es) | 2020-03-11 |
| CL2020000898A1 (es) | 2020-08-14 |
| EP3693358A4 (en) | 2021-06-02 |
| JP2019065009A (ja) | 2019-04-25 |
| TW201922706A (zh) | 2019-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020115045A (ru) | Азотсодержащее гетероарильное соединение и его фармацевтическое применение | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| EA202190116A1 (ru) | Агент для профилактики или лечения спинальной мышечной атрофии | |
| EA201992884A2 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| RU2020110780A (ru) | Ингибитор fgfr и его медицинское применение | |
| RU2016118399A (ru) | Производные 4-аминометилбензойной кислоты | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| JP2013531029A5 (enExample) | ||
| RU2018121288A (ru) | Ингибиторы ионного канала, фармацевтические составы и применение | |
| JP2016518434A5 (enExample) | ||
| RU2019142472A (ru) | Глюкуронидные пролекарства ингибиторов янус-киназы | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| EA201690458A1 (ru) | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы | |
| RU2019130519A (ru) | 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав | |
| ES2659222T3 (es) | 7-azabicíclicos sustituidos y su uso para moduladores de receptores de orexina | |
| RU2014112048A (ru) | Пиразольное соединение и его применение в фармацевтике | |
| JO3811B1 (ar) | مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv | |
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2020520955A5 (enExample) | ||
| RU2011112684A (ru) | АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α | |
| JP2019065009A5 (enExample) | ||
| RU2019121926A (ru) | Ингибитор CDK4/6 | |
| EA201692189A1 (ru) | Соединения фосфина золота (i) в качестве антибактериальных агентов | |
| EA201692190A1 (ru) | Соединения фосфина золота (i) в качестве антибактериальных агентов |